SCHEMBL68990

SCHEMBL68990

O=S(=O)(Cl)c1ccc(F)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 3/20 0.58
AKR1B1 P15121 1/20 0.49
EPHX2 P34913 1/20 0.39
KMT2A Q03164 1/20 0.38
PFKFB3 Q16875 1/20 0.38
BRD4 O60885 3/20 0.37
CNR2 P34972 1/20 0.37
ACLY P53396 2/20 0.37
CCR2 P41597 2/20 0.37
MCL1 Q07820 1/20 0.37
PTGS2 P35354 1/20 0.37
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
PTGES2 Q9H7Z7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651884 1.00 TRPV4 (0.58) TRPV4AKR1B1EPHX2KMT2APFKFB3
SCHEMBL1060711 0.83 TRPV4 (0.44) TRPV4AKR1B1KMT2AACLYMCL1
SCHEMBL27619523 0.83 AKR1B1 (0.49) TRPV4AKR1B1EPHX2KMT2APFKFB3
SCHEMBL644001 0.81 CCR2 (0.50) TRPV4AKR1B1BRD4CNR2CCR2
SCHEMBL6038484 0.81 AKR1B1 (0.47) TRPV4AKR1B1EPHX2KMT2APFKFB3
SCHEMBL1942774 0.81 CA1 (0.48) AKR1B1PTGES2
SCHEMBL30860761 0.81 AKR1B1 (0.47) TRPV4AKR1B1EPHX2KMT2APFKFB3
SCHEMBL2050647 0.81 AKR1B1 (0.47) TRPV4AKR1B1EPHX2KMT2APFKFB3
SCHEMBL113810 0.80 AKR1B1 (0.46) TRPV4AKR1B1ACLYCCR2
SCHEMBL29899701 0.80 AKR1B1 (0.46) TRPV4AKR1B1ACLYCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119425423-A Positively charged composite membrane and preparation method and application thereof 中国石油化工股份有限公司 2025-02-14 CN claimed
CN-109608369-A Sulphonyl ester group anthraquinone derivatives and its preparation method and application 广西大学 2019-04-12 CN claimed
CN-104678028-A Pretreatment and detection method for biogen amine neurotransmitter and detection kit INST PHARM & TOXICOLOGY AMMS 2015-06-03 CN claimed
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP claimed
EP-1968651-A2 STABILIZED COMPOSITIONS AND METHODS FOR RADIOLABELING PHARMACEUTICALS WITH ALPHA-PARTICLE EMITTERS Duke University (US) 2008-09-17 EP claimed
WO-2007120251-A2 STABILIZED COMPOSITIONS AND METHODS FOR RADIOLABELING PHARMACEUTICALS WITH ALPHA-PARTICLE EMITTERS DUKE UNIVERSITY (US) 2007-10-25 WO claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
CN-122079918-A Isoxazole biphenyl compounds with CBP BRD and BRD4 BD2 inhibitory activity, and preparation method and application thereof 2026-05-26 CN disclosed
WO-2026104681-A1 NEW SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 WO disclosed
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 CN disclosed
US-12577257-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2026-03-17 US disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
EP-1036063-A1 HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-09-20 EP disclosed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO disclosed
US-6037356-A ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-03-14 US disclosed
WO-1999031092-A1 BENZAMINE DERIVATIVES MERCK PATENT GMBH (DE) 1999-06-24 WO disclosed
WO-1999026926-A1 HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-06-03 WO disclosed
EP-0917528-A1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-05-26 EP disclosed
WO-1998001422-A1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1998-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS TRPV4 3761/4885AKR1B1 636/4885EPHX2 2214/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD TRPV4 3686/4885AKR1B1 619/4885EPHX2 2214/4885
US-12577257-B2 Heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 TRPV4 3806/4885AKR1B1 1042/4885EPHX2 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.